Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jiri Kalabis, Kenji Oyama, Takaomi Okawa, Hiroshi Nakagawa, Carmen Z. Michaylira, Douglas B. Stairs, Jose-Luiz Figueiredo, Umar Mahmood, J. Alan Diehl, Meenhard Herlyn, Anil K. Rustgi
Published in Volume 118, Issue 12
J Clin Invest. 2008; 118(12):3860–3869 doi:10.1172/JCI35012
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
BrdU LRCs reside in the basal compartment.

(A and B) After 1 month of BrdU administration and immediate processing of tissues, almost all basal cells were BrdU+ (arrowheads). Original magnification, ×100 (A), ×400 (B). (CF) BrdU+ cells (arrowheads) were restricted in their spatial localization after 1 month of BrdU administration and 2 weeks (C and D) and 4 weeks (E and F) of tissue processing after cessation of BrdU administration. Original magnification, ×100 (C and E), ×400 (D and F). (G and H) Immunofluorescence revealed that BrdU+ cells (red; arrowhead) were pan-CK+ (green; arrows), establishing their epithelial origin. Nuclei were counterstained with DAPI. Original magnification, ×100 (G), ×400 (H). Scale bars: 25 μm.